Protocol Ledger

NCT03632135 · Phase III · COMPLETED

Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma

Interventional Phase III clinical trial protocol NCT03632135 sponsored by Cordgenics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-20 Enrollment: 78 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03632135
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)78 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03632135
Protocol FieldVerified Registry Value
NCT IdentifierNCT03632135
Consolidated Lead SponsorCordgenics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment78 participants (ACTUAL)
Registered Start Date2018-05-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03632135
Hospital Research SiteLocationSite Profile
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->
University of Mississippi Medical CenterJackson, MSOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI